Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Advanced Solid Tumors: early-phase trial registry
70 of 145 indexed Advanced Solid Tumors trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #81 of 28,707 conditions by registered trial count.
145 US clinical trials · 70 currently recruiting · #81 of 28,707 conditions by registered trial count
Advanced Solid Tumors: 145 US clinical trials tracked, 70 recruiting.
Advanced Solid Tumors is the subject of 145 registered US clinical trials on ClinicalTrials.gov, 70 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 144 in Phase 1-2 (earlier-stage). The most active sponsor is Amgen, running 5 of these trials.
Enrollment posture brief
Registry condition advanced-solid-tumors
OPEN 70 | RECR 48% | LATE 1 | EARLY 144 | RANK #81 | SPON 5
Volume-matched condition peers
Nearest open-share peer: Gynecologic Cancer (48% recruiting · 56 trials)
Advanced Solid Tumors lists 70 open slots (48% of 145 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Advanced Solid Tumors on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Advanced Solid Tumors is recruiting above its size-band peers.
70 of 145 indexed trials (48.3%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Advanced Solid Tumors trials is spread across many organizations.
Amgen accounts for 5 of 145 trials (3.4%). 100 distinct sponsors appear on at least one study for this condition label.
-
Typical Advanced Solid Tumors enrolment sits around 120 participants.
Median target enrolment is 120 among the 145 trials that report a genuine target (sentinel values excluded). 63 of those (43.4%) plan for fewer than 100 participants.
-
Advanced Solid Tumors research is mostly interventional.
145 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
145 total, page 3 of 3
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
Novartis Pharmaceuticals
NCT01576666
A Phase 1 Study of RO7623066 Alone and in Combination in Patients With Advanced Solid Tumors
Hoffmann-La Roche
NCT05240898
A Phase 1 Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®)
Astellas Pharma
NCT00739453
Study of Continuous OSI-906 Dosing
Astellas Pharma
NCT00514007
Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors
Five Prime Therapeutics
NCT02318329
A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors
Pfizer
NCT04672460
A First In Patient, Study Of Investigational Drug PF-03446962 In Patients With Advanced Solid Tumors
Pfizer
NCT00557856
A Study of HGS1029 (AEG40826-2HCl) in Subjects With Advanced Solid Tumors
Human Genome Sciences
NCT00708006
Study of Mogamulizumab + MEDI4736 (Durvalumab) and Mogamulizumab + Tremelimumab in Subjects w/ Advanced Solid Tumors
Kyowa Kirin
NCT02301130
Phase 1 Study of OSI-930 in Cancer Patients
Astellas Pharma
NCT00513851
A Study of ABT-806 in Subjects With Advanced Solid Tumor Types
AbbVie (prior sponsor, Abbott)
NCT01255657
Safety of TT-00420 (Tinengotinib) Monotherapy in Patients With Advanced Solid Tumors and Triple Negative Breast Cancer
TransThera Sciences (Nanjing)
NCT03654547
Study of Plitidepsin in Combination With Sorafenib or Gemcitabine in Patients With Advanced Solid Tumors or Lymphomas
PharmaMar
NCT00788099
Effect of Sapanisertib (MLN0128) on the QTc Interval in Participants With Advanced Solid Tumors
Calithera Biosciences
NCT02197572
Phase I Safety Study of the Drug MM-121 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment
Merrimack Pharmaceuticals
NCT00734305
A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment
Taiho Oncology
NCT02301117
A Study of ARRY-520 in Patients With Advanced Cancer
Array Biopharma, now a wholly owned subsidiary of Pfizer
NCT00462358
An Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800)
Pfizer
NCT02997176
Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple Myeloma
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ U
NCT00996957
AMG 386 Drug-Drug Interaction Study With Paclitaxel
Amgen
NCT01992341
Dose-Escalation Phase 1 Study of G-202 (Mipsagargin) in Patients With Advanced Solid Tumors
GenSpera
NCT01056029
Study of Intravenous TCD-717 in Patients With Advanced Solid Tumors
Traslational Cancer Drugs Pharma, SL
NCT01215864
Safety Study of IMC-18F1,to Treat Advanced Solid Tumors in Subjects That no Longer Respond to Standard Therapy
Eli Lilly and Company
NCT00782002
Food Effect Study of Alisertib (MLN8237) in Participants With Advanced Solid Tumors or Lymphomas
Millennium Pharmaceuticals
NCT01898078
Pharmacokinetics and Safety of Panobinostat in Patients With Advanced Solid Tumors and Various Degrees of Hepatic Function
Novartis Pharmaceuticals
NCT01007968
A Study of AMG 820 in Subjects With Advanced Solid Tumors
AmMax Bio
NCT01444404
A Study of CS1001 in Subjects with Advanced Solid Tumors
CStone Pharmaceuticals
NCT03744403
Phase 1 Trial of the LSD1 Inhibitor SP-2577 (Seclidemstat) in Patients With Advanced Solid Tumors
Salarius Pharmaceuticals
NCT03895684
First-in-human Study of M4076 in Advanced Solid Tumors (DDRiver Solid Tumors 410)
EMD Serono Research & Development Institute
NCT04882917
Effect of Rifampin on the Pharmacokinetics of Ixabepilone in Patients With Advanced Cancer
R-Pharm
NCT00207090
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC61in Subjects With Advanced Solid Tumors
Ascletis Pharmaceuticals Co.
NCT05287399
Safety Study of ON 01910.Na in Combination With Irinotecan or Oxaliplatin
Traws Pharma
NCT00861328
A Phase 1/2, Open-Label, Dose-Escalation Study of JI-101, in Patients With Advanced Solid Tumors
Jubilant Innovation
NCT00842335
MK-2206, Paclitaxel and Trastuzumab in Treating Patients With HER2-overexpressing Solid Tumor Malignancies
University of California, San Francisco
NCT01235897
Safety, Tolerability, and Immunoregulatory Activity of Mogamulizumab (KW-0761) in Subjects With Advanced and/or Metastatic Solid Tumors
Memorial Sloan Kettering Cancer Center
NCT02281409
A Study of IMC-A12 Every 2 Weeks in Patients With Tumors Who No Longer Respond to Treatment or No Treatment is Available
Eli Lilly and Company
NCT00785941
Effect of Rifampin on the Pharmacokinetics of Linifanib in Subjects With Advanced or Metastatic Solid Tumors
Abbott
NCT01401933
A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial
Astellas Pharma Global Development
NCT02057380
Study of Oral Darinaparsin in Patients With Advanced Solid Tumors
Alaunos Therapeutics
NCT01139346
Study of AMG 994 Monotherapy and AMG 994 and AMG 404 Combination Therapy in Participants With Advanced Solid Tumors
Amgen
NCT04727554
Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 Trial
Astellas Pharma Global Development
NCT02561455
Study of the Mass Balance of Oral FTD and TPI as Components of TAS-102 in Patients With Advanced Solid Tumors
Taiho Oncology
NCT02031055
A Study to Look at How a Single Oral Dose of 14C-OSI-906 is Absorbed, Broken Down and Eliminated in the Body
Astellas Pharma Global Development
NCT01529684
Study of NK012 and Carboplatin in Solid Tumors With Dose Expansion in Triple Negative Breast Cancer
Nippon Kayaku Co.
NCT01238952
Mass Balance, Pharmacokinetics and Metabolism Study of Alisertib
Millennium Pharmaceuticals
NCT01714947
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 137 |
| Phase 2 | 7 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Advanced Solid Tumors records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Advanced Solid Tumors trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Advanced Solid Tumors page
145 registered trials, 70 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 70 Advanced Solid Tumors trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Amgen sponsors the most Advanced Solid Tumors trials on record, review their full trial history before evaluating a specific study. See Amgen's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Advanced Solid Tumors condition card totals 145 registered trials; most-linked intervention Pembrolizumab; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.